tegafur and Pancreatic Neoplasms studies

Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Research Excerpts

Excerpt	Relevance	Reference
"To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)."	9.41	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021)
"The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma."	9.22	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016)
"Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites."	9.22	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016)
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites."	9.19	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014)
"This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma."	9.16	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."	7.88	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1."	7.78	Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. ( Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012)
" Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer."	7.77	A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011)
" The aim of this study was to determine the effect of adjuvant gemcitabine and S-1 therapy for patients with adenocarcinoma of the body or tail of the pancreas who had undergone surgical resection by distal pancreatectomy."	7.75	Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2009)
"Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks."	7.74	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2008)
"Grade 3 neutropenia was common (35%)."	6.90	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"To investigate the efficacy and safety of nab-paclitaxel plus S-1 (nab-P/S) versus nab-paclitaxel plus gemcitabine (nab-P/G) as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma (PDAC)."	5.41	Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. ( Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y, 2021)
"Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea."	5.38	[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012)
"The objective of this study was to determine the recommended dose (RD) of a biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable pancreatic ductal adenocarcinoma."	5.22	Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. ( Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H, 2016)
"Objectives The aim of this study was to evaluate the safety and efficacy of intravenous and intraperitoneal paclitaxel (PTX) combined with S-1 for treatment of gemcitabine-refractory pancreatic cancer with malignant ascites."	5.22	Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. ( Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N, 2016)
"Here, we reported an interim analysis of feasibility and safety in the first 10 cases of 30 cases in a phase II trial of intravenous and intraperitoneal paclitaxel combined with S-1 for gemcitabine-refractory pancreatic cancer with malignant ascites."	5.19	Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H, 2014)
"This study evaluated long-term outcomes for patients who received adjuvant gemcitabine plus S-1 chemotherapy after resection for pancreatic carcinoma."	5.16	Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K, 2012)
" There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor."	5.14	Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients. ( Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K, 2010)
"Eligibility criteria were histologically proven pancreatic adenocarcinoma with confirmation of progressive disease while receiving gemcitabine-based first-line chemotherapy, 20-74 years of age, Karnofsky performance status of 80-100 points, with measurable metastatic lesions, adequate hematological, renal and liver functions, and written informed consent."	5.14	A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. ( Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H, 2009)
"Nab-paclitaxel plus S1 was more efficient in terms of ORR and DCR than S1 monotherapy in elderly pancreatic ductal adenocarcinoma patients while the side effect was controllable with a higher probability of leukopenia."	5.12	Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patients: A meta-analysis. ( Chen, D; Chen, X; Chen, Y; Cui, S; Du, J; Gu, J; Lin, Z; Luo, H; Ma, C; Wang, C; Yang, L; Yin, M, 2021)
"The objectives of this study were to evaluate the efficacy and toxicity of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur (UFT) in patients with advanced adenocarcinoma of the pancreas."	5.10	Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. ( Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE, 2002)
"In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)."	5.04	[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979)
"Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades."	3.88	S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma. ( Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB, 2018)
"Objective To explore the efficacy and toxicities of gemcitabine combined with S-1 in treating locally advanced and metastatic pancreatic ductal adenocarcinoma and prognostic factors."	3.85	Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer. ( Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N, 2017)
"In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1."	3.78	Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. ( Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y, 2012)
" Here, we report the case of a patient with systemic sclerosis who developed severe digital ischemia during combination gemcitabine/S-1 chemotherapy for pancreatic cancer."	3.77	A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. ( Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C, 2011)
" The aim of this study was to determine the effect of adjuvant gemcitabine and S-1 therapy for patients with adenocarcinoma of the body or tail of the pancreas who had undergone surgical resection by distal pancreatectomy."	3.75	Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2009)
"The subjects consisted of 23 patients with pancreatic adenocarcinoma who had liver metastases and were treated with S-1 and gemcitabine as the first-line treatment."	3.74	Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis. ( Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O, 2008)
"Patients admitted for curative surgery for pancreatic adenocarcinoma received adjuvant chemotherapy with 10 cycles of gemcitabine plus S-1 every 2 weeks."	3.74	Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. ( Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K, 2008)
"BACKGROUND Pancreatic cancer (PC) is a common digestive system tumor."	2.94	A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. ( Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J, 2020)
" According to the prescribed protocol of the clinical trial, statistical analyses included 57 phase 2 patients and 6 phase 1 patients who received the same dosage as in phase 2."	2.90	A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma. ( Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y, 2019)
"Resminostat is an oral hydroxamate inhibitor of class I, IIb, and IV histone deacetylases."	2.90	Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. ( Hara, R; Hashimoto, Y; Ikeda, M; Kobayashi, S; Kondo, S; Mitsunaga, S; Morizane, C; Nakamura, O; Ohno, I; Okusaka, T; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H, 2019)
"Grade 3 neutropenia was common (35%)."	2.90	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. ( Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K, 2019)
"Gemcitabine was administered at a dose of 1000 mg/m2 by 30 min infusion on days 1, S-1 40 mg/m2 orally twice daily and LV 25 mg orally twice daily on days 1 to 7 every 2 weeks."	2.90	A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. ( Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N, 2019)
"Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40-60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40-60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle)."	2.90	TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). ( Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S, 2019)
"Few patients with pancreatic cancer may be candidates for immediate surgical resection at the initial diagnosis."	2.90	Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). ( Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X, 2019)
" A total of 185 patients with inoperable or metastatic pancreatic cancer who were refractory or intolerant to standard primary chemotherapy with gemcitabine plus nab-paclitaxel will be allocated to secondary treatment either with placebo in combination with S-1 (the control group) or TLP0-001 in combination with S-1 (the investigational product group)."	2.90	A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. ( Adachi, T; Akahori, T; Asahara, S; Endo, I; Fujii, T; Furukawa, M; Hakamada, K; Hara, K; Ioka, T; Katanuma, A; Katsuda, M; Kitano, M; Miyazawa, M; Nagano, H; Ohira, M; Ojima, T; Satoi, S; Sudo, K; Ueno, M; Yamada, S; Yamaue, H, 2019)
" We examined the safety of WT1-peptide pulsed dendritic cell (WT1-DC) vaccine in combination with chemotherapy in patients with surgically resected pancreatic cancer."	2.87	WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. ( Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R, 2018)
"Patients with pancreatic cancer commonly suffer from exocrine pancreatic insufficiency, and the ingestion of digestive enzyme supplements may improve absorption."	2.87	Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. ( Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K, 2018)
" This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A)."	2.84	A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. ( Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A, 2017)
"Borderline resectable pancreatic cancer (BRPC) can involve the portal vein, superior mesenteric vein, superior mesenteric artery, coeliac axis or hepatic artery, and has a high probability of positive surgical margins and poor prognosis after resection."	2.84	Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05). ( Akimoto, T; Ikeda, M; Kobayashi, T; Kojima, M; Konishi, M; Ohno, I; Takahashi, S; Uesaka, K, 2017)
"Paclitaxel was administered i."	2.84	Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. ( Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H, 2017)
"S-1 for advanced pancreatic cancer should be taken daily as recommended, based on the decreased OS and PFS and marginal improvement in safety observed in the alternate-day group."	2.84	Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. ( Hagiwara, Y; Hashimoto, D; Imaoka, H; Isayama, H; Ishii, H; Kitano, M; Maguchi, H; Nagakawa, T; Nakamori, S; Nebiki, H; Ohashi, Y; Ohkawa, S; Shimizu, A; Shirasaka, T; Sho, M; Sugimori, K; Ueda, K; Ueno, H; Yamaue, H; Yanagimoto, H; Yokota, I, 2017)
"In the GEST study of unresectable pancreatic cancer, S-1 demonstrated non-inferiority compared to gemcitabine, but gemcitabine plus S-1 (GS) did not show superiority over gemcitabine for overall survival (OS)."	2.82	Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study. ( Egawa, S; Hara, K; Hijioka, S; Imaoka, H; Kou, T; Mizuno, N; Shimizu, Y; Tanaka, M; Yamao, K; Yazumi, S, 2016)
"In the surgical treatment of pancreatic cancer, margin-negative status is one of the most important determinants of survival."	2.82	Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors. ( Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S, 2016)
"Locally advanced pancreatic cancer (LAPC) is associated with high mortality, and biomarker-driven treatment approach is currently lacking."	2.82	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. ( Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D, 2016)
"Patients with resected pancreatic cancer were randomly assigned (in a 1:1 ratio) to receive gemcitabine (1000 mg/m(2), intravenously administered on days 1, 8, and 15, every 4 weeks [one cycle], for up to six cycles) or S-1 (40 mg, 50 mg, or 60 mg according to body-surface area, orally administered twice a day for 28 days followed by a 14 day rest, every 6 weeks [one cycle], for up to four cycles) at the data centre by a modified minimisation method, balancing residual tumour status, nodal status, and institutions."	2.82	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). ( Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R, 2016)
"Patients who had undergone resection of pancreatic cancer were registered in this randomized clinical trial."	2.80	Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection. ( Katoh, M; Kubota, K; Shimizu, T; Shimoda, M, 2015)
"Patients with unrespectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400 mg/m(2), 5 mg/m(2)/min) on days 1, 8, 22, and 29 and 60 mg/m(2) of S-1 orally on days 1-14, 22-35."	2.80	A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. ( Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K, 2015)
"Patients with advanced pancreatic cancer were eligible for enrollment in this trial."	2.79	Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer. ( Chijiiwa, K; Egawa, S; Hayashi, K; Hirono, S; Kanbe, T; Kato, J; Kawai, M; Kwon, AH; Miyazawa, M; Mukouyama, T; Ohuchida, J; Okada, K; Satoi, S; Shirasaka, T; Tani, M; Tsunoda, H; Ueda, K; Yamaguchi, T; Yamaue, H; Yanagimoto, H, 2014)
"The long-term prognosis for localized pancreatic cancer (PC) remains poor."	2.79	Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. ( Ikari, T; Ioka, T; Isayama, H; Ishii, H; Koike, K; Kwon, AH; Nakai, Y; Okusaka, T; Ozaka, M; Satoi, S; Shimokawa, T; Sho, M; Tanaka, M; Ueno, H; Yanagimoto, H, 2014)
"Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m(2) over 30 min on day 1, and oral S-1 at a dose of 40 mg/m(2) twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1-7, every 2 weeks."	2.79	A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N, 2014)
"In this study, we compared the efficacy and safety of the oral fluoropyrimidine S-1 as monotherapy or in combination with leucovorin as the second-line treatment for patients with metastatic pancreatic cancer whose disease had progressed on gemcitabine treatment."	2.79	S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. ( Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y, 2014)
"Pancreatic cancer is one of the most aggressive cancers with a median survival time (MST) of <6 months in chemotherapy-resistant patients."	2.78	A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. ( Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S, 2013)
" The dosage of S-1 was based on the body surface area (BSA) as follows: 40 mg bid (total 80 mg/day) for a BSA of <1."	2.78	Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. ( Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY, 2013)
"Irinotecan (100 mg/m(2)) was administered on days 1, 8, and 15 every 4 weeks until disease progression or unacceptable toxicity was observed."	2.78	Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. ( Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y, 2013)
"Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy."	2.76	A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. ( Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K, 2011)
"To investigate the efficacy and toxicity of a short intensive Uracil/Tegafur (UFT) based chemoradiotherapy scheme combined with celecoxib in locally advanced pancreatic cancer."	2.76	Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. ( Busch, OR; Morak, MJ; Nuyttens, JJ; Padmos, EE; Richel, DJ; Schaake, EE; van der Gaast, A; van Eijck, CH; van Tienhoven, G; Vervenne, WL, 2011)
"Gemcitabine 1250 mg/m² was administered on the 1st and 8th days of the cycle, tegafur 750 mg/m²/day for 21 consecutive days and LV 25 mg/day continuously, every 28 days, with a maximum of six cycles."	2.76	Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer. ( Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E, 2011)
"Gemcitabine was administered at a dose of 1000 mg/m(2) over 30 min on days 1 and 8, and oral S-1 at a dose of 40 mg/m(2) twice daily from days 1 to 14, repeated every 3 weeks."	2.76	Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. ( Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O, 2011)
" GEM was administrated at a dosage of 1 g/m(2) intravenously weekly 3 of 4 weeks and UFT at a dosage of 200 mg/day orally continuously."	2.73	A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. ( Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H, 2008)
"Although the prognosis in patients with pancreatic cancer has been poor, we recently reported unusually high response rate and survival benefit of S-1 treatment in patients with pancreatic cancer."	2.73	High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1. ( Danenberg, KD; Danenberg, PV; Hatori, T; Hayashi, K; Kuramochi, H; Nakajima, G; Uchida, K; Yamamoto, M, 2008)
"A total of 208 cycles of chemotherapy were given with a median of 4 per patient."	2.72	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. ( Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG, 2006)
" In total, 79 courses were administered with a median of 3 (range 1-6)."	2.72	UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors. ( Abad, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gallego, J; Gómez, A; López, E; Manzano, JL; Sastre, J, 2006)
"We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients."	2.72	Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. ( Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006)
"The incidence and mortality of pancreatic cancer has increased very rapidly in Japan."	2.72	[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer]. ( Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T, 2006)
" Administration of more than 2 courses was attempted for each patient, with the same dosage levels at all 3 scheduled steps."	2.71	[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer]. ( Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K, 2004)
" Therefore, we conducted a phase II study of gemcitabine combined with UFT in metastatic pancreatic cancer patients and assessed the efficacy and the toxicity of the regimen."	2.71	Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY, 2004)
"The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC)."	2.71	Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. ( Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T, 2005)
") gemcitabine (GEM) at low dose plus oral chemotherapy with uracil-tegafur (UFT) and cyclophosphamide (CPA) in combination with radiotherapy (RT) against recurrent and advanced pancreatic cancers."	2.71	Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer. ( Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S, 2005)
"Uracil-tegafur (UFT) has been reported to have a broad anti-tumor activity in a variety of malignancies including colorectal cancer and breast cancer."	2.70	Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002)
" The potential benefit of long bioavailability and oral delivery of UFT compares favorably with continuous infusion regimens without the added morbidity of a catheter and pump."	2.69	A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer. ( Bonner, JA; Childs, HA; Newsome, J; Raben, D; Robert, F; Spencer, SA, 2000)
"UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer."	2.68	UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. ( Mani, S, 1997)
" The optimal dosage was considered to be between 17 mg/kg and 24 mg/kg."	2.65	[Joint clinical Phase II study of SF-SP]. ( Hanatani, Y; Sato, H; Sato, T, 1984)
" The combined hazard ratio (HR) or risk ratio; the corresponding 95% confidence intervals of progression-free survival, overall survival, and overall response rate; and grade 3-4 adverse events were examined."	2.53	Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis. ( Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X, 2016)
"After decades of research, pancreatic cancer is still a devastating disease."	2.52	Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. ( Jiang, Z; Li, Y; Liu, G; Sun, J; Zhang, L, 2015)
"G-CSF producing anaplastic carcinoma of the pancreas is extremely rare and there are no reports with regard to response evaluation by FDG-PET."	2.49	[An autopsy of G-CSF-producing anaplastic carcinoma of the pancreas with impaired accumulation on FDG-PET after S-1 chemotherapy]. ( Ikeda, S; Ito, T; Kanazawa, H; Katada, N; Morita, K; Narita, M; Nishimura, D; Okubo, K; Shibahara, H; Takeuchi, A, 2013)
"Treatment of locally advanced pancreatic cancer is challenging."	2.44	Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? ( Kim, R; Saif, MW, 2007)
"The early diagnosis of pancreatic cancer is difficult because of the lack of specific early symptoms,and surgery with curative intent can be performed in only 20% of patients."	2.44	[Treatments of pancreatic cancer from the standpoint of medical oncology]. ( Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E, 2007)
"Moreover, pancreatic cancer in most patients is surgically unresectable at the time of diagnosis."	2.43	[Recent important insights into treatment of pancreatic cancer]. ( Abe, N; Atomi, Y; Sugiyama, M, 2005)
"Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%."	2.36	[Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978)
" This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(hereafter referred to as the A+GS regimen) in the first-line treatment of patients with unresectable or metastatic PC."	1.91	A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer. ( Da, S; Fang, F; Hu, J; Liu, S; Luo, P; Shen, E; Su, Y; Wen, F; Weng, J; Xu, M; Zhan, D; Zhan, G; Zhou, C; Zhou, Q, 2023)
"We aimed to evaluate pancreatic cancer (PC) with positive peritoneal lavage cytology (CY1) outcomes following a change in adjuvant therapy."	1.72	Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study. ( Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H, 2022)
"However, pancreatic cancer is non-immunogenic, and single agent immunotherapies are unfavorable to its prognosis."	1.62	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. ( Ye, Y; Zheng, S, 2021)
"Sarcopenia has been reported to be associated with reduced antitumor response and chemotherapy toxicity in several malignancies."	1.62	The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. ( Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y, 2021)
"Lymph node metastasis was an independent risk factor for both locoregional (P < 0."	1.62	Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. ( Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H, 2021)
"Unresectable pancreatic cancer (UR-PC) has a poor prognosis."	1.56	Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy. ( Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y, 2020)
"Pancreatic cancer is a fatal malignancy that frequently occurs in older patients."	1.51	Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study. ( Babazono, A; Fujita, T; Harano, Y; Jiang, P, 2019)
"Fifty-four patients with resected pancreatic cancer were enrolled."	1.51	Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer. ( Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H, 2019)
"5-year survival rate of pancreatic cancer is as low as about 6."	1.48	[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy]. ( Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Nishikura, K; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A; Watanabe, G, 2018)
" Hematological adverse events were commonly seen in both group (12."	1.48	Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. ( Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y, 2018)
"Chemotherapy for unresectable pancreatic cancer has moved from using gemcitabine (GEM) and/or S-1 to using 5- fluorouracil plus Leucovorin plus oxaliplatin plus irinotecan (FOLFIRINOX) or GEM and nano albumin-bound paclitaxel (nab- PTA)."	1.48	[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer]. ( Saito, K; Sato, A; Takahata, T; Yu, C, 2018)
"Gemcitabine plus S-1 was generally used as neoadjuvant chemotherapy."	1.46	Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Okada, K; Sudo, T; Sueda, T; Takahashi, S; Uemura, K, 2017)
"Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC."	1.46	Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017)
" The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment."	1.46	Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report. ( Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017)
"Sixty-five patients with advanced pancreatic cancer were enrolled."	1.46	Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. ( Arigami, T; Kijima, Y; Kurahara, H; Maemura, K; Mataki, Y; Matsushita, D; Natsugoe, S; Okubo, K; Sakoda, M; Uenosono, Y; Yanagita, S, 2017)
"Three human pancreatic cancer cell lines were treated with S-1, nab-paclitaxel, alone or in combination."	1.43	S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. ( Fujii, T; Fujiwara, M; Kanda, M; Kodera, Y; Koike, M; Nakayama, G; Suenaga, M; Sugimoto, H; Tanaka, C; Yamada, S, 2016)
"We made a diagnosis of pancreatic cancer, and the patient underwent pancreaticoduodenectomy."	1.43	[A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. ( Aoyama, T; Atsumi, Y; Kazama, K; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Rino, Y; Shiozawa, M; Ueno, M; Washimi, K; Yukawa, N, 2016)
"The regrowth of an isolated local residual tumor without a distant metastasis was diagnosed 65 months after the resection."	1.43	[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein]. ( Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E, 2016)
" With regard to adverse events, the rates of nausea (p<0."	1.42	[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015)
"These results suggest that S-1 adjuvant chemotherapy for pancreatic cancer is safe and feasible, regardless of the age of the patient, especially for elderly patients who may be candidates for clinical trials."	1.42	Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. ( Aoyama, T; Atsumi, Y; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Oshima, T; Rino, Y; Shiozawa, M; Ueno, M; Yamamoto, N; Yamaoku, K; Yoshikawa, T, 2015)
"The prognosis of Stage IV b pancreatic cancer is extremely poor; the mean survival time is 2-4 months."	1.42	[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy]. ( Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T, 2015)
"Chemotherapy for unresectable pancreatic cancer should not only prolong survival but maintain quality of life, considering its limited life expectancy."	1.42	Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. ( Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K, 2015)
" The efficacy and adverse reactions in patients of the study and control groups were observed and compared."	1.42	[Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer]. ( He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H, 2015)
"A 64-year-old man was diagnosed with pancreatic cancer by abdominal computed tomography (CT)."	1.42	[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy]. ( Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K, 2015)
"We encountered a case of pancreatic cancer with multiple liver metastases that developed postoperatively and showed a complete response with S-1 monotherapy for a long time."	1.42	[A Case of Pancreatic Cancer with Multiple Liver Metastases That Developed Postoperatively and Showed a Complete Response with S-1 Monotherapy]. ( Asai, K; Baba, M; Hiratsuka, M; Katsuyama, S; Murata, M; Saso, K; Sawami, H; Takahashi, H; Takayama, O; Tanaka, N; Yagi, T; Yamada, M; Yamamoto, M, 2015)
" Pancreaticoduodenectomy combined with hepatic artery resection was performed, and an end-to-end anastomosis was made between the common and proper hepatic artery to reconstruct the hepatic artery."	1.42	[A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy]. ( Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H, 2015)
"The tumor was diagnosed as unresectable pancreatic cancer, and chemotherapy of gemcitabine and S-1 was administered, resulting in a remarkable reduction of the tumor size."	1.42	[Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report]. ( Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S, 2015)
"Patients with borderline resectable pancreatic cancer have a poorer prognosis than patients with resectable pancreatic cancer, but some cases treated with neoadjuvant chemoradiation therapy and radical surgery (R0 surgery) show long-term survival."	1.42	[A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy]. ( Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyahara, Y; Miyazaki, M; Nishida, T; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H, 2015)
"The prognosis of pancreatic cancer is dismal compared to other types of cancer, and for a Stage Ⅳb cancers, the 5-year survival rate is reported to be approximately 3%."	1.42	[Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy]. ( Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K, 2015)
"Fifty-two patients with pancreatic cancer who underwent surgical resection were enrolled in this study."	1.40	Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. ( Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2014)
"We report two cases of pancreatic cancer with multiple liver metastases for which successful gemcitabine (GEM) +S-1 therapy facilitated radical resection."	1.40	[Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy]. ( Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y, 2014)
"The tumor thrombus extended to the bifurcation of the portal vein."	1.40	[A case of resection for a huge pancreatic acinar cell carcinoma with tumor thrombus in the portal vein]. ( Aisu, Y; Andoh, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T, 2014)
"In terms of biomarkers in pancreatic cancer, Neoptolemos et al."	1.39	Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer? ( Chaulagain, CP; Rothschild, J; Saif, MW, 2013)
"Because the pancreatic cancer recurred 4 months after surgery, however, he was treated with combination chemotherapy(S- 1+GEM at 750mg/m2)."	1.39	[Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine]. ( Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M, 2013)
"Pancreatic cancer is frequently complicated by malignancies in other organs."	1.39	Synchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 followed by pancrelipase treatment of pancreatic exocrine insufficiency. ( Gabata, T; Ikeda, H; Ishikawa, D; Iwakami, S; Matsui, O; Mouri, H; Nanjo, S; Ohtsubo, K; Takamatsu, Y; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K, 2013)
"A case of recurrent pancreatic cancer effectively responded to S-1 and irinotecan combined with third-line chemotherapy (IRIS) with PSK."	1.39	[A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK]. ( Asano, T; Ishii, M; Iwata, K; Kobayashi, H; Kobayashi, S; Koizumi, S; Okamura, R; Otsubo, T; Saji, O; Sumiyoshi, K, 2013)
"Patients with PR (n=14) and BR (n=13) pancreatic cancer who received NAC (n=15) or NAC-RT (n=12) were enrolled in our study."	1.39	[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy]. ( Desaki, R; Higashi, M; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S, 2013)
"Diabetes mellitus was diagnosed in 124 patients (50%) who had less distant metastasis and more hypertension."	1.39	Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. ( Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yamamoto, N, 2013)
"Prevention of postoperative complication is needed to enable early initiation."	1.39	Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. ( Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K, 2013)
"Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea."	1.38	[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012)
"The prognosis for pancreatic cancer with distant metastasis is not good."	1.38	[Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases]. ( Fujioka, M; Fukui, H; Kou, C, 2012)
"Chemo-naïve patients with unresectable pancreatic cancer were enrolled."	1.37	Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. ( Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T, 2011)
" Though grade 3 neutropenia appeared after 2 courses of the combined therapy, the patient well tolerated it after controlling the dosing schedule."	1.37	[A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy]. ( Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K, 2011)
"A 71-year-old male with unresectable pancreatic cancer treated with gemcitabine (GEM) by another doctor came to our hospital because of stenosis of duodenum and hydronephrosis."	1.37	[A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy]. ( Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y, 2011)
"Patients with severe metastatic pancreatic cancer received chemotherapy comprising S-1 (30mg/m² p."	1.37	[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis]. ( Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S, 2011)
"A 62-year-old woman with a diagnosis of pancreatic cancer with splenic invasion, liver metastasis, and peritoneal dissemination was scheduled to receive chemotherapy."	1.37	[A long-term survivor who received S-1-based multidisciplinary therapy for unresectable advanced pancreatic cancer]. ( Kametaka, H; Koyama, T; Makino, H; Seike, K, 2011)
"Lapatinib is a small molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR)."	1.36	In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer. ( Amano, R; Hirakawa, K; Kawajiri, H; Komoto, M; Nakata, B; Nishii, T; Shinto, O; Yamada, N; Yashiro, M, 2010)
"The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1."	1.36	Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. ( Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N, 2010)
" However, many patients are often forced to give up long-term S-1 treatment owing to high incidence rates of adverse effects."	1.36	[Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan]. ( Hazama, S; Nakazawa, S; Suga, T; Watanabe, S; Yagi, M; Yoshino, S, 2010)
"In total, 112 patients with pancreatic cancer who received chemotherapy between April 2001 and April 2007 were divided into 2 groups: PreS-1 (53 patients who started chemotherapy before January 2005) and PostS-1 (59 patients who started chemotherapy after February 2005, the time of S-1 introduction)."	1.36	Impact of S-1 on the survival of patients with advanced pancreatic cancer. ( Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2010)
"Pancreatic cancer is among the most lethal of all digestive cancers, and it is very difficult to obtain long-term survival of unresectable cases."	1.36	[A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer]. ( Miyagawa, K; Sagara, Y; Yamaoka, N; Yata, Y, 2010)
"FDG-PET was highly suggestive of pancreatic cancer (T4N1M0, Stage IVa) with lymph node metastasis."	1.36	[A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy]. ( Arakawa, A; Hisama, S; Kimura, M; Matsushita, H; Nishimura, T; Okamura, S; Saitoh, S; Shimokawa, Y; Tanaka, Y; Toyama, H, 2010)
"The prognosis for pancreatic cancer with distant metastases is not good."	1.36	[S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis]. ( Fukui, H; Kou, C; Matsumoto, M; Matsumoto, T, 2010)
"In the case of pancreatic cancer that CRT is effective to the remission of primary lesion, CRT is potentially useful to perform for the control of metastatic lesion or palliative therapy."	1.36	[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy]. ( Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N, 2010)
" This study was to evaluate the efficacy of three-dimensional conformal gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer."	1.35	[Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer]. ( Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP, 2008)
"The prognosis for advanced pancreatic cancer with peritoneal dissemination is extremely poor, and no effective standard therapy has been established."	1.35	[Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report]. ( Inaba, K; Konno, H; Okamoto, N, 2009)
"Abdominal CT scan revealed pancreatic cancer with massive ascites showing peritoneal dissemination, combined with lymph node and liver metastases."	1.35	[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases]. ( Fushida, S; Kimura, H; Mukawa, A, 2009)
"Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction."	1.35	Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. ( Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H, 2009)
"17 unresectable pancreatic cancer patients who came for consultation between November 2001 and August 2008 (ten men, seven women)."	1.35	[Effectiveness of S-1 therapy for unresectable/advanced pancreas cancer]. ( Imamoto, R; Kanbe, T; Kishimoto, Y; Kojo, H; Mukouyama, T; Nishimuki, E; Shabana, M; Tsunoda, H, 2009)
"Gemcitabine was administered at a dose of 1,000 mg/m(2) in a 30-min intravenous injection on days 1 and 15."	1.35	A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. ( Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y, 2009)
"Gemcitabine (1,000 mg/m2) was intravenously administered 3 times (on days 1, 8, 15) every 4 weeks (days 1-28) as 1 course."	1.35	[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer]. ( Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T, 2009)
"We report a long-term survival case of pancreatic cancer with hepatic metastasis after surgical resection treated by S-1 and gemcitabine combination chemotherapy."	1.35	[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy]. ( Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K, 2009)
"Examination revealed locally advanced pancreatic cancer with infiltration of the superior mesenteric artery."	1.35	Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case. ( Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N, 2009)
"Current therapy for advanced pancreatic cancer focuses largely on gemcitabine."	1.35	Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. ( Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J, 2008)
"Pancreas cancer or gallbladder cancer was suspected by CT, and a high tumor marker score (CA19-9 18,625 U/mL, DUPAN-II 15,000 U/ mL elevations were acknowledged)."	1.35	[Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: further diagnosis of disseminated carcinomatosa of bone marrow recurrence ( Aoyama, I; Arai, O; Doi, A; Hata, T; Hirao, K; Jinno, A; Katayama, S; Kikuchi, O; Kiyosuke, Y; Maeda, Y; Matsueda, K; Miyoshi, M; Mouri, H; Sakai, A; Tanabe, W; Terashima, Y; Tsuji, Y; Yamamoto, H; Yamamoto, N, 2008)
"We reported a case of unresectable gastric cancer presenting pylorus stenosis treated orally by S-1 therapy in a 72-year-old man who underwent gastrojejunostomy."	1.34	[A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy]. ( Matsui, K; Morita, S; Shinbo, M; Tazawa, K; Tsukada, K; Yamada, A; Yamagishi, F; Yoshida, T, 2007)
"We report a patient with gastric cancer successfully treated with TS-1 and low-dose CDDP as neoadjuvant chemotherapy."	1.33	[A Case of advanced gastric cancer successfully treated with TS-1/low-dose CDDP as neoadjuvant chemotherapy]. ( Ebina, T; Kawasaki, H; Kobori, H; Sasaki, M; Seino, K; Shibata, S; Sugiyama, Y; Tanaka, M; Yamada, K, 2005)
"He was diagnosed as having advanced pancreatic cancer by enhanced abdominal CT scan in May 2004."	1.33	[A case of advanced pancreatic cancer treated with chemoradiation]. ( Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M, 2005)
"Pancreatic acinar cell carcinomas are rare, and little is reported on their chemotherapy."	1.33	[Pancreatic acinar cell carcinoma successfully treated with combination of oral TS-1 and intra-arterial cisplatin]. ( Endo, S; Hashimoto, K; Higami, T; Itagaki, T; Itakura, M; Kataoka, Y; Koike, M; Nio, Y; Nishi, T; Yano, S, 2006)
"The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy."	1.33	[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease]. ( Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T, 2006)
"Gemcitabine uptake was significantly increased when cells were treated with 5-FU."	1.33	Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. ( Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K, 2006)
"At present, the advanced pancreatic cancer is known to be one of the most resistant malignancies on chemotherapy."	1.33	[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S, 2006)
"In two patients with advanced pancreatic cancer with cervical lymph node or liver metastasis and no indication of pancreatic resection and radiotherapy, oral treatment with S-1 (an anti-cancer agent of fluoropyrimidine derivative) exerted high anti-tumor activity on the metastatic lesions."	1.33	[Two cases of advanced pancreatic cancer with cervical lymph node or liver metastasis responding well to S-1 monotherapy]. ( Funakoshi, A; Senju, T; Sumii, T, 2006)
"We report two metastatic pancreatic cancer patients who showed marked tumor shrinkage following administration of the oral fluorinated pyrimidine anticancer drug, S-1."	1.33	[Two patients effectively treated by S-1 monotherapy for metastatic pancreatic cancer]. ( Ikeda, M; Ueno, H, 2006)
"Grade 3 neutropenia was observed, but no other severe toxicities were noted."	1.33	[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report]. ( Boku, N; Fukutomi, A; Yoshino, T, 2006)
"The prognosis and QOL of unresectable pancreatic cancer are very poor."	1.32	[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003)
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)."	1.32	[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003)
"Tegafur dose was 1,200 mg/d along the external radiotherapy period (45-55 consecutive days)."	1.32	Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. ( Calvo, FA; García-Sabrido, JL; Gómez-Espí, M; Herranz, R; Lozano, MA; Martínez, NE; Matute, R, 2004)
"Thirty four patients with advanced gastric cancer (GC), colon cancer (CC) biliary tract cancer (BC) and pancreatic cancer (PC) were treated with a combined chemotherapy of UFT with ADM (UFT-A), or UFT with ADM and CDDP (UFT-AC)."	1.28	[Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer]. ( Koda, K; Kure, T; Matsunaga, T; Miyazaki, E; Morii, K; Morita, K; Nakajima, K; Nakazawa, O; Terada, S; Tsuji, Y, 1990)
"One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks."	1.27	[Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984)
"Two patients who had unresectable pancreatic cancer were treated with a combined chemotherapy using Cisplatin, PSK and UFT."	1.27	[Two cases of unresectable pancreatic cancer responding to combined chemotherapy with cisplatin, PSK and UFT]. ( Kanda, M; Kitagawa, T; Mutoh, E; Namiki, M; Okamura, K; Okano, S; Sohma, M; Suzuki, Y; Takeda, S; Utsumi, M, 1987)
"Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients."	1.27	[Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics]. ( Fukushi, A; Hirayama, M; Koda, K; Kure, T; Morita, K; Nakazawa, O; Takahashi, H; Terada, S; Terui, T; Yoshizaki, N, 1988)
"One hundred forty-three patients with pancreatic cancer were treated with a number of chemotherapeutic agents, while ninety-eight patients did not receive any chemotherapy."	1.27	[Clinical study on the effect of chemotherapy in the treatment of pancreatic cancer]. ( Fujimoto, T; Ishida, T; Kurogoh, F; Ohyanagi, H; Okumura, S; Saitoh, Y; Shimada, Y; Tagashira, Y; Uchida, K; Yamamoto, M, 1988)
"The incidence of pancreatic cancer has been increasing in recent years."	1.27	[Chemotherapy of pancreatic cancer]. ( Nakamura, K; Ozaki, H; Tajiri, H; Yoshimori, M, 1985)
"These included 7 cases of pancreatic cancer, 2 cases of gall bladder cancer with infiltration to the liver, and 3 cases of hepatoma."	1.27	[Clinical study on concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after rectal administration of FT-207 suppositories for malignant diseases of the liver, biliary tract and pancreas]. ( Hasegawa, H; Takada, T; Uchiyama, K; Yasuda, H, 1985)

Research

Studies (412)

Authors

Clinical Trials (16)

Trial Overview

Trial Outcomes

Median Overall Survival Will be Determined.

Timeframe	Studies, this research(%)	All Research%
pre-1990	23 (5.58)	18.7374
1990's	15 (3.64)	18.2507
2000's	108 (26.21)	29.6817
2010's	238 (57.77)	24.3611
2020's	28 (6.80)	2.80

Authors	Studies
Kobayashi, S	13
Ueno, M	15
Ogawa, G	1
Fukutomi, A	10
Ikeda, M	23
Okusaka, T	26
Sato, T	5
Ito, Y	11
Kadota, T	1
Ioka, T	11
Sugimori, K	5
Sata, N	5
Nakamori, S	15
Shimizu, K	1
Mizuno, N	7
Ishii, H	14
Furuse, J	23
Deng, GC	1
Lv, Y	1
Yan, H	1
Sun, DC	1
Qu, TT	1
Pan, YT	1
Han, QL	1
Dai, GH	1
Ye, Y	1
Zheng, S	2
Todaka, A	2
Nara, S	1
Motoi, F	11
Morinaga, S	8
Toshiyama, R	1
Higuchi, R	4
Konishi, M	6
Shirakawa, H	2
Tsumura, H	1
Okuyama, H	2
Nagano, H	9
Shioji, K	2
Sugimachi, K	2
Asagi, A	2
Takumoto, Y	1
Sasahara, Y	1
Narimatsu, H	2
Akazawa, M	1
Tomimaru, Y	3
Eguchi, H	7
Inoue, Y	3
Nagakawa, Y	3
Ohba, A	2
Takami, H	2
Unno, M	13
Yamamoto, T	9
Kawakatsu, S	2
Hayashi, T	4
Kitagawa, H	3
Hattori, S	2
Fujii, T	7
Hirooka, Y	4
Igarashi, H	3
Kitano, M	6
Kuroki, T	2
Masamune, A	3
Shimizu, Y	6
Tani, M	4
Tanno, S	4
Tsuji, Y	4
Yamaue, H	7
Satoi, S	14
Takeyama, Y	3
Zhan, G	1
Hu, J	2
Da, S	1
Weng, J	1
Zhou, C	1
Wen, F	3
Liu, S	1
Fang, F	2
Shen, E	1
Zhou, Q	1
Luo, P	1
Xu, M	1
Zhan, D	1
Su, Y	1
Takeda, Y	4
Takahashi, H	8
Nakahira, S	3
Kashiwazaki, M	1
Shimizu, J	1
Sakai, D	1
Isohashi, F	1
Mori, M	6
Doki, Y	6
Miyashita, T	2
Tajima, H	2
Gabata, R	1
Okazaki, M	1
Shimbashi, H	1
Ohbatake, Y	1
Okamoto, K	4
Nakanuma, S	2
Sakai, S	1
Makino, I	2
Kinoshita, J	1
Hayashi, H	8
Nakamura, K	15
Takamura, H	2
Ninomiya, I	1
Fushida, S	2
Harmon, JW	1
Ohta, T	3
Liao, W	1
Huang, J	1
Zhu, G	1
Zhou, J	4
Zhang, P	2
Zhou, K	1
Wu, Q	1
Wang, X	2
Gou, H	2
Li, Q	2
Chen, HW	1
Kuo, HY	1
Chen, BB	1
Tien, YW	1
Kuo, SH	1
Yang, SH	1
Okamura, Y	3
Yasukawa, S	1
Boku, N	12
Toyama, H	5
Kaneoka, Y	3
Yamakita, K	1
Takahashi, A	1
Kainuma, O	3
Hishinuma, S	3
Yamaguchi, R	3
Nagino, M	2
Hirano, S	3
Yanagisawa, A	1
Mori, K	1
Uesaka, K	5
Morimoto, Y	6
Takada, K	1
Takeuchi, O	3
Takagi, A	1
Watanabe, K	2
Hirohara, M	1
Hamamoto, T	1
Masuda, Y	1
Yang, PC	2
Huang, KW	2
Pua, U	2
Kim, MD	2
Li, SP	2
Li, XY	1
Liang, PC	2
Ono, H	1
Kudo, A	2
Akahoshi, K	2
Ogura, T	2
Ogawa, K	1
Ban, D	2
Tanaka, S	4
Tanabe, M	1
Hayashi, Y	1
Matsuo, Y	2
Hamano, S	1
Oba, A	2
Ueda, G	1
Omi, K	1
Imafuji, H	1
Saito, K	5
Tsuboi, K	1
Morimoto, M	5
Ogawa, R	1
Takiguchi, S	1
Tsuchiya, N	1
Matsuyama, R	3
Murakami, T	2
Yabushita, Y	2
Sawada, Y	2
Kumamoto, T	2
Endo, I	4
Iede, K	1
Yamada, T	2
Kato, R	1
Ueda, M	2
Tsuda, Y	1
Nakashima, S	1
Ohta, K	1
Matsuyama, J	2
Ikenaga, M	2
Tominaga, S	1
Imaoka, H	3
Maehara, K	1
Umemoto, K	1
Ozaka, M	4
Terashima, T	1
Inoue, H	1
Sakaguchi, C	1
Tsuji, K	1
Okamura, K	2
Kawamoto, Y	1
Suzuki, R	2
Morizane, C	13
Cui, H	1
Guan, J	1
Deng, G	1
Yuan, J	2
Lou, C	1
Zhang, W	1
Zhou, A	1
Zhang, Y	4
Dai, G	1
Matsuda, Y	1
Ohkubo, S	1
Nakano-Narusawa, Y	1
Fukumura, Y	1
Hirabayashi, K	2
Yamaguchi, H	4
Sahara, Y	2
Kawanishi, A	1
Takahashi, S	7
Arai, T	1
Kojima, M	2
Mino-Kenudson, M	1
Zong, Y	1
Peng, Z	1
Lu, M	1
Shen, L	1
Yan, X	1
Ning, ZY	1
Wang, P	1
Zhuang, LP	1
Xu, LT	1
Zhu, ZF	1
Sheng, J	1
Shen, YH	1
Hua, YQ	1
Meng, ZQ	1
Chen, CY	1
Liang, SH	1
Su, YY	1
Chiang, NJ	1
Wang, HC	1
Chiu, CF	1
Chen, LT	1
Bai, LY	1
Takeda, T	2
Sasaki, T	13
Mie, T	1
Furukawa, T	2
Yamada, Y	5
Kasuga, A	2
Matsuyama, M	3
Sasahira, N	10
Izumo, W	1
Yazawa, T	1
Uemura, S	1
Matsunaga, Y	1
Shiihara, M	1
Yamamoto, M	10
Liang, L	1
Ding, Y	1
Yu, Y	1
Liu, K	1
Rao, S	2
Ge, Y	1
Zeng, M	1
Li, B	1
Shen, S	1
You, S	1
Zhang, G	1
Gao, S	2
Shi, X	2
Wang, H	1
Yin, X	1
Xu, X	1
Guo, S	2
Jin, G	2
Hashimoto, D	3
Yamaki, S	3
Ishida, M	2
Ryota, H	3
Sakaguchi, T	2
Hirooka, S	3
Inoue, K	4
Sekimoto, M	2
Hirono, S	2
Kawai, M	2
Okada, KI	1
Miyazawa, M	3
Kitahata, Y	1
Kobayashi, R	1
Hayami, S	1
Chen, Y	1
Gu, J	1
Yin, M	1
Wang, C	1
Chen, D	2
Yang, L	2
Chen, X	1
Lin, Z	1
Du, J	1
Cui, S	1
Ma, C	1
Luo, H	1
Murakami, Y	11
Uemura, K	11
Sudo, T	12
Hashimoto, Y	11
Kondo, N	8
Nakagawa, N	7
Okada, K	5
Sueda, T	10
Hosokawa, Y	1
Nakayama, H	1
Takishita, C	1
Nakajima, T	4
Hijikata, Y	1
Kasuya, K	1
Katsumata, K	1
Tokuuye, K	1
Tsuchida, A	2
Hamada, C	3
Ikari, T	3
Isayama, H	18
Nakai, Y	13
Imai, S	3
Okamura, S	3
Mori, R	2
Taniguchi, K	3
Sakamaki, K	1
Kubota, K	2
Sudo, K	10
Hara, R	2
Kita, E	1
Tsujimoto, A	1
Yamaguchi, T	16
Okano, K	1
Suto, H	1
Oshima, M	1
Maeda, E	1
Yamamoto, N	12
Kakinoki, K	2
Kamada, H	1
Masaki, T	3
Shibata, T	2
Suzuki, Y	4
Miyagawa, F	1
Sugano, Y	1
Sho, M	8
Asada, H	1
Zhong, S	1
Qie, S	1
Yan, Q	1
Ge, L	1
Wang, Z	1
Cheng, YJ	2
Meng, CT	1
Shao, YJ	1
Li, NN	1
Zhou, N	1
Yan, XY	1
Gao, X	1
Zhou, JF	1
Bai, CM	1
Ohno, I	3
Kobayashi, T	3
Akimoto, T	1
Yokode, M	1
Itai, R	1
Yamashita, Y	3
Zen, Y	1
Winther, SB	1
Bjerregaard, JK	4
Schonnemann, KR	1
Ejlsmark, MW	1
Krogh, M	1
Jensen, HA	3
Pfeiffer, P	4
Wei, J	1
Dong, X	1
Du, F	1
Tang, S	1
Wei, H	1
Kamei, K	1
Matsumoto, I	8
Makutani, Y	1
Kawaguchi, K	2
Matsumoto, M	2
Murase, T	1
Nakai, T	1
Kamata, K	1
Imai, H	1
Chikugo, T	1
Matsui, H	1
Sakamoto, K	3
Matsukuma, S	1
Tokumitsu, Y	1
Tokuhisa, Y	1
Kanekiyo, S	1
Tomochika, S	1
Iida, M	2
Suzuki, N	1
Takeda, S	4
Yoshino, S	2
Hazama, S	2
Ueno, T	1
Ueda, N	3
Fujii, Y	1
Miura, S	2
Fujita, J	1
Tomita, Y	1
Ohnishi, T	1
Fujita, H	1
Kinami, S	1
Omote, K	1
Nakano, Y	3
Kosaka, T	2
Motoo, Y	3
Fujita, S	1
Matsukawa, H	2
Shiozaki, S	2
Satoh, D	1
Idani, H	1
Ojima, Y	2
Harano, M	2
Nakano, K	2
Sumitani, D	1
Choda, Y	2
Miyake, S	1
Kubota, T	1
Okajima, M	1
Lee, BM	1
Chung, SY	1
Chang, JS	2
Lee, KJ	1
Seong, J	3
Nakachi, K	6
Mizusawa, J	1
Eba, J	1
Fukuda, H	1
Zhu, X	3
Liu, D	1
Song, J	1
Zhang, H	3
Lu, J	1
Hagiwara, Y	2
Ohashi, Y	5
Sakamoto, H	2
Imai, K	3
Ojima, H	2
Umebayashi, Y	1
Fukunari, H	1
Kawai, Y	1
Aoki, M	3
Watanabe, A	1
Saito, T	4
Shitara, K	3
Nishikura, K	1
Watanabe, G	3
Ajioka, Y	1
Yanagisawa, R	1
Koizumi, T	1
Koya, T	1
Sano, K	4
Koido, S	2
Nagai, K	1
Kobayashi, M	4
Okamoto, M	2
Sugiyama, H	2
Shimodaira, S	2
Abe, K	1
Uwagawa, T	2
Haruki, K	1
Takano, Y	1
Onda, S	1
Sakamoto, T	3
Gocho, T	2
Yanaga, K	3
Xu, Y	1
Guo, X	1
Fan, Y	1
Wang, D	1
Wu, W	1
Wu, L	1
Liu, T	1
Xu, B	1
Feng, Y	1
Wang, Y	2
Lou, W	1
Zhou, Y	2
Yamada, D	2
Iwagami, Y	1
Asaoka, T	3
Noda, T	2
Kawamoto, K	5
Gotoh, K	2

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II Trial Comparing Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Patients With Advanced Pancreatic Cancer[NCT03636308]	Phase 2	40 participants (Anticipated)	Interventional	2018-07-17	Recruiting
Phase II Study of Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer[NCT02459652]	Phase 2	57 participants (Actual)	Interventional	2012-12-28	Completed
Phase II Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas[NCT03779464]	Phase 2	132 participants (Anticipated)	Interventional	2019-08-01	Recruiting
Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients[NCT05955157]	Phase 2/Phase 3	52 participants (Anticipated)	Interventional	2023-01-03	Recruiting
Comparisons of Different Neoadjuvant Chemotherapy Regimens With or Without Stereotactic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer: Study Protocol of a Prospective, Randomized Phase II Trial[NCT03777462]	Phase 2	150 participants (Anticipated)	Interventional	2019-04-01	Recruiting
Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792]	Phase 2	27 participants (Anticipated)	Interventional	2020-05-09	Recruiting
Stereotactic Body Radiation Therapy With Sequential S-1 for Patients With Locally Advanced Pancreatic Cancer and Poor Medical Conditions --a Phase II Clinical Trial[NCT02704143]		63 participants (Actual)	Interventional	2016-02-29	Completed
Randomized Phase III Study of Gemcitabine Versus TS-1 Versus Gemcitabine Plus TS-1 in Unresectable Advanced Pancreatic Cancer (With Local Progression or Metastasis)[NCT00498225]	Phase 3	834 participants (Actual)	Interventional	2007-07-31	Completed
An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527]	Phase 2	30 participants (Anticipated)	Interventional	2021-09-03	Recruiting
Nivolumab as add-on to Gemcitabine/S-1 in Metastatic Pancreatic Cancer: a Phase II Trial[NCT04377048]	Phase 2	38 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers[NCT01074996]	Phase 2	92 participants (Actual)	Interventional	2010-02-28	Active, not recruiting
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529]	Phase 2	28 participants (Anticipated)	Interventional	2021-03-01	Recruiting
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study[NCT03002831]	Phase 2	13 participants (Actual)	Interventional	2016-11-30	Terminated (stopped due to Study halted prematurely and will not resume)
A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150]	Phase 2/Phase 3	231 participants (Anticipated)	Interventional	2020-01-05	Recruiting
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study[NCT04737551]		400 participants (Anticipated)	Observational [Patient Registry]	2020-01-01	Recruiting
Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy[NCT05298722]		45 participants (Anticipated)	Interventional	2022-12-12	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Median overall survival is calculated by Kaplan-Meier method. (NCT02704143)
Timeframe: 3 years

Number of Participants With Acute Toxicities Following SBRT

Intervention	months (Median)
Combination of Cyberknife With S-1	14.4

The acute toxicities are determined by RTOG Acute Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: Within 90 days after completion of SBRT

Number of Participants With Late Toxicities Following SBRT

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	9

The late toxicities are determined by RTOG/EORTC Late Radiation Morbidity Scoring Criteria. (NCT02704143)
Timeframe: 90 days after SBRT

One-year Overall Survival Rate

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	5

One-year overall survival rate is calculated by the ratio of number of patients surviving more than 1 year to the total number of patients enrolled. (NCT02704143)
Timeframe: 1 year

The Median Progression Free Survival Time Will be Determined.

Intervention	Participants (Count of Participants)
Combination of Cyberknife With S-1	46

Progression-free survival is the time from the date of enrollment to the confirmation of disease progression at any sites, including local progression or metastasis, or death from any causes, if this occurred before disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02704143)
Timeframe: 3 years

The Quality of Life Will be Analyzed.

Intervention	months (Median)
Combination of Cyberknife With S-1	10.1

The analysis of quality of life is based on The European Organization for Reasearch and Treatment of Cancer (EORTC): Quality of Life Questionnare-Core 30 (QLQ-C30). Higher scores in function domains and global health status indicate better quality of life, while higher scores in symptom domains imply worse quality of life. The scale range of all domains of QLQ-C30 is 0-100 (the minimum and maximum score is 0 and 100 points, respectively). (NCT02704143)
Timeframe: 1 years

Intervention	units on a scale (Mean)
	Global health status	Physical functioning	Role functioning	Emotional functioning	Cognitive functioning	Social functioning	Fatigue	Nausea and vomiting	Pain	Dyspnea	Insomnia	Appetite loss	Constipation	Diarrhea	Financial difficulties
Combination of Cyberknife With S-1	50.0	64.2	54.8	68.5	73.8	74.6	46.7	55.3	48.7	9.5	19.0	59.2	13.2	13.7	31.2

tegafur and Pancreatic Neoplasms